Long‐Term Results with a Slow‐Release Gonadotrophin‐Releasing Hormone Agonist in Central Precocious Puberty
- 1 January 1991
- journal article
- clinical trial
- Published by Wiley in Acta Paediatrica
- Vol. 80 (s372) , 39-45
- https://doi.org/10.1111/j.1651-2227.1991.tb17967.x
Abstract
As part of an ongoing international multicentre study, 19 children (14 girls, 5 boys) with central precocious puberty (CPP) were treated with a slow‐release gonadotrophin‐releasing hormone (GnRH) agonist, triptorelin, for 4 years. After 3 years of treatment, height velocity stabilized at 4.0 cm/year. Predicted adult height (mean ± SD) increased from 158.9 ± 6.8 to 164.9 ± 6.6 cm in girls (n = 14, p < 0.01), and from 174.4 ± 18.5 to 184.3 ± 17.1 cm in boys (n = 4, p < 0.05). In 12 additional girls who had started the multicentre study but discontinued triptorelin treatment after 2.2 ± 0.5 years, menses started 9.8 ± 3.7 months after cessation of treatment in all but one patient. Height velocity increased over the first 6 months after discontinuation of treatment, from 3.6 ± 0.1 to 5.4 ± 2.5 cm/year, and remained higher than pretreatment values in the second 6 months, but decreased subsequently. Bone maturation increased, and no significant improvement in predicted adult height was observed. For auxological reasons, therefore, it may be advisable to continue triptorelin treatment for as long as possible. Concomitant growth hormone (GH) therapy was initiated in three girls with CPP with height velocities of 3.2–3.6 cm/year after 3 years of treatment with triptorelin and predicted adult heights of less than the third centile for Dutch girls. Prior to the administration of GH, all patients had subnormal 24‐hour GH profiles and GH responses to arginine provocation. GH treatment increased height velocity markedly in all girls, and improved predicted adult height. It is concluded that triptorelin therapy improves predicted adult height. In children with CPP and genetic short stature, with a markedly decreased height velocity during triptorelin therapy, concomitant administration of a GnRH agonist and GH may have advantages. Further extensive studies are required.Keywords
This publication has 20 references indexed in Scilit:
- Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonistEuropean Journal of Pediatrics, 1990
- Pubertal Development, Growth and Final Height in Girls with Sexual Precocity after Therapy with the GnRH Analogue D-TRP-6-LHRHHormone Research, 1990
- Six-year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious pubertyThe Journal of Pediatrics, 1989
- Growth, Growth Hormone and Sex Steroid Secretion in Girls with Central Precocious Puberty Treated with a Gonadotrophin Releasing Hormone (GnRH) AnalogueActa Paediatrica, 1988
- The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious pubertyEuropean Journal of Pediatrics, 1987
- Growth hormone secretory dynamics in children with precocious pubertyThe Journal of Pediatrics, 1987
- Treatment of Central Precocious Puberty with an LHRH Agonist (Buserelin): Effect on Growth and Bone Maturation after Three Years of TreatmentHormone Research, 1987
- Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted heightPublished by American Medical Association (AMA) ,1986
- Somatomedin-C in accelerated growth of children with precocious pubertyThe Journal of Pediatrics, 1985
- Tables for predicting adult height from skeletal age: Revised for use with the greulich-pyle hand standardsThe Journal of Pediatrics, 1952